Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

184.71B

Market cap184.71B

Price-Earnings ratio

24.61

Price-Earnings ratio24.61

Dividend yield

2.76%

Dividend yield2.76%

Average volume

2.56M

Average volume2.56M

High today

$350.23

High today$350.23

Low today

$342.41

Low today$342.41

Open price

$350.23

Open price$350.23

Volume

104.32K

Volume104.32K

52 Week high

$391.29

52 Week high$391.29

52 Week low

$261.43

52 Week low$261.43

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $342.64. The company's market cap stands at 184.71B, with a P/E ratio of 24.61 and a dividend yield of 2.8%.

On 2026-04-21, Amgen(AMGN) stock moved within a range of $342.41 to $350.23. With shares now at $342.64, the stock is trading +0.1% above its intraday low and -2.2% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 104.32K, versus its average volume of 2.56M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $261.43.

AMGN News

TipRanks 3h

Amgen initiated with a Hold at Canaccord

Canaccord last night initiated coverage of Amgen (AMGN) with a Hold rating and $366 price target Amgen has executed well on its key growth drivers, but this is...

Simply Wall St 2d

Will Amgen’s Subcutaneous Tepezza Success Reshape Viridian Therapeutics' Thyroid Eye Disease Narrative?

In recent days, Viridian Therapeutics has come under renewed attention after Amgen reported positive Phase 3 results for a subcutaneous version of Tepezza in mo...

Simply Wall St 4d

Assessing Whether Amgen Still Looks Undervalued After Recent Share Price Pullback

Advertisement Context for Amgen (AMGN) after recent price moves Recent trading in Amgen (AMGN) has drawn attention after a modest 0.3% gain over the past day...

Analyst ratings

53%

of 38 ratings

Buy

39.5%

Hold

52.6%

Sell

7.9%

More AMGN News

TipRanks 6d

Limited Near-Term Growth and Patent Headwinds Drive Underperform Rating on Amgen

Analyst Tazeen Ahmad of Bank of America Securities reiterated a Sell rating on Amgen, retaining the price target of $304.00. Unlock hedge fund-level data and p...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.